

Substitute for form 1449A&B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	10/660,112
Filing Date	September 10, 2003
First Named Inventor	Luskey, Kenneth L.
Art Unit	1632
Examiner Name	Rebecca Cook
Attorney Docket Number	016325-003721US

U.S. PATENT DOCUMENTS+


Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JDA	AA	US-5,716,987	02-10-1998	Wille	
JDA	AB	US-2004/0204472	10-14-2004	Briggs	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
JDA	AB1	WO	92/17435		10-15-1992	Weber et al.		<input checked="" type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JDA	AC	BROOKS, D. A. et al., "Design and Synthesis of 2-Methyl-2-[4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy] propionic Acids: A New Class of Dual PPAR α Agonists," <i>J. Med. Chem.</i> , 44:2061-2064 (2001)	
	AD	DORFLER, H. et al., "Primarer Verteilungsraum und Plasmahalbwertszeit von intravenously verabreichtem Insulin," <i>Med. Poliklinik Univ. Muenchen</i> pp. 1297-1299 (1973)	
	AE	FANELLI, G.M., Jr. "Renal Excretion and Uricosuric Properties of Halofenate A Hypolipidemic Uricosuric Agent in the Chimpanzee," <i>J. Pharmacol. Exp. Ther.</i> , 180:377-396 (1972)	
	AF	GAVIN III, J.R. et al., "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus," <i>Diabetes Care</i> , 22:S5-S19 (1999)	
	AG	JAIN, A. et al., "Potentiation of Hypoglycemic Effect of Sulfonylureas by Halofenate," <i>New England J. of Med.</i> 293:25, pp. 1283-1286 (1975)	
	AH	KOBAYASHI, M. et al., "Improvement of Glucose Tolerance in NIDDM by Clofibrate," <i>Diabetes Care</i> , 11:6, pp. 495-499 (1988)	
	AI	KRUT, L. H. et al., "Comparison of Clofibrate with Halofenate in Diabetics with Hyperlipidaemia," <i>S. A. Med. J.</i> , pp. 348-352 (1977)	
	AJ	MANDEL, L. R., "Studies on the Mechanism of Action of Halofenate," <i>Lipids</i> , 12:1, pp. 34-43 (1976)	
	AK	McMAHON, F.G. et al., "Some Effects of MK-185 on Lipid and Uric Acid Metabolism in Man," <i>Univ. Mich. Med. Center J.</i> , 36(4):247-248 (1970)	
JDA	AL	NEUMAN, J. et al., "A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia," <i>J. Cardiovasc. Surg. Torino, Spec. No.</i> 32-7:532-537 (1973)	

Examiner
SignatureDate
Considered


4/12/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/660,112
				Filing Date	September 10, 2003
				First Named Inventor	Luskey, Kenneth L.
				Art Unit	1632
				Examiner Name	Rebecca Cook
Sheet	2	of	2	Attorney Docket Number	016325-003721US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JDA	AM	SCHAEFFER, S., "Trying to beat PPAR," <i>BioCentury, The Bernstein Report on BioBusiness</i> , pp. 1-3, (Reprint from June 14, 2004)	
	AN	SCHLOSSTEIN, L.H. et al. "Studies with some novel uricosuric agents and their metabolites: correlation between clinical activity and drug-induced displacement of urate from its albumin-binding sites," <i>J. Lab. Clin. Med.</i> , 82:412-418 (1973)	
	AO	TURNER, N.C. et al., "Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities," <i>Progress in Drug Research</i> , 51:34-94 (1998)	
	AP	VEDELL, E.S. et al., "Differential Effects of Chronic Halofenate Administration on Drug Metabolism in Man," <i>Fed. Proc.</i> , 31:538 (1972)	
	AQ	WRIGHT A.D., et al., "UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes," <i>Diabetes Care</i> , 21:87-92 (1998)	
JDA	AR	METABOLEX, The Diabetes Biopharmaceutical Company, "Metabolic Diseases Drug Discovery & Development Summit," <i>Strategic Research Institute</i> , (May 6-7, 2002)	

Examiner Signature		Date Considered	4/12/2006
-----------------------	---	--------------------	-----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.